The California Institute of Regenerative Medicine CIRM has awarded Ossium Health, Inc. a $3.46M Clinical Stage Research Program CLIN1 grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory acute graft versus host disease (GVHD).
This investment will assist and accelerate pre-clinical and manufacturing operations for OSSM-007, with clinical study activities expected to begin by the end of 2023.
The California Institute of Regenerative Medicine (CIRM) has awarded Ossium Health, Inc. a $3.46M Clinical Stage Research Program (CLIN1) grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory acute graft versus host disease (GVHD).
This investment will assist and accelerate pre-clinical and manufacturing operations for OSSM-007, with clinical study activities expected to begin by the end of 2023.
Ossium Health is a bioengineering business that uses its unique dead donor bone marrow banking technology to develop cell therapeutics for hematologic illnesses, organ rejection, and orthopedic injuries.
The company, which was founded in 2016, is run by its co-founders, President & CEO Kevin Caldwell and EVP & Chief Science Officer Erik Woods. The company’s objective is to use bioengineering to improve human health, vitality, and longevity.
